Answers are grounded in this paper and cite their sources.
Levodopa replacement therapy has long provided the most effective treatment for Parkinson's disease (PD). We review how this dopamine (DA) precursor enhances dopaminergic transmission by providing a greater sphere of neurotransmitter influence as a result of the confluence of increased quantal size and decreased DA reuptake, as well as loading DA as a false transmitter into surviving serotonin neuron synaptic vesicles. We further review literature on how presynaptic dysregulation of DA release after l-dopa might trigger dyskinesias in PD patients.
No takes yet. Share an insight, caveat, or question.
Mosharov et al. (2014) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: